Expanded Access Policy for TSN1611
Tyligand is currently conducting clinical trials to evaluate the safety and efficacy of TSN1611, a selective KRAS G12D inhibitor.
Tyligand does not currently offer an expanded access program for TSN1611, and no expanded access application process is available at this time. At this stage of clinical development, Tyligand believes that participation in a clinical trial is the most appropriate way for patients to access TSN1611.
For information about ongoing clinical trials of TSN1611, including recruitment status and study locations, patients and healthcare professionals are encouraged to visit ClinicalTrials.gov and search “TSN1611”.
This policy reflects Tyligand‘s current position on expanded access to TSN1611 and is subject to change at the discretion of Tyligand in the future.
Tyligand Bioscience is a clinical-stage biotech company founded in 2017, focusing on the discovery and development of innovative cancer therapeutics. The company commenced business operations in 2018. Leveraging decades of profound experience in leading drug discovery and development at multinational pharmaceutical companies, the management team has successfully established technology platforms with fully integrated capabilities across small molecules and antibody-drug conjugates (ADCs). Serving as an innovation engine, these platforms have enabled the company to build a diversified pipeline encompassing multiple drug candidates.
Consistently driven by the mission to address significant unmet clinical needs, Tyligand Bioscience is dedicated to becoming a leading global biopharmaceutical enterprise. By continuously delivering high-quality, differentiated innovative therapies, the company aims to improve the quality of life for patients worldwide and create long-term commercial value.
For more info about Tyligand Bioscience, please visit www.tyligand.com.cn
- Tyligand Bioscience